Durable Complete Remission With Combination of Stereotactic Body Radiation Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in Refractory Metastatic Melanoma

Zachary Wolfe; Aaron Blackham; Alyson McIntosh; Angela Miller; Hina Sheikh; Suresh Nair

doi:10.7759/cureus.29573

Durable Complete Remission With Combination of Stereotactic Body Radiation Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in Refractory Metastatic Melanoma

Cureus. 2022 Sep 25;14(9):e29573. doi: 10.7759/cureus.29573. eCollection 2022 Sep.

Authors

Zachary Wolfe¹, Aaron Blackham², Alyson McIntosh³, Angela Miller¹, Hina Sheikh⁴, Suresh Nair⁵

Affiliations

¹ Hematology and Medical Oncology, Lehigh Valley Topper Cancer Institute, Allentown, USA.
² Surgical Oncology, Lehigh Valley Topper Cancer Institute, Allentown, USA.
³ Radiation Oncology, Lehigh Valley Cancer Institute, Allentown, USA.
⁴ Pathology, Health Network Laboratories, Allentown, USA.
⁵ Hematology and Oncology, Lehigh Valley Cancer Institute, Allentown, USA.

Abstract

Metastatic melanoma refractory to checkpoint inhibitors is a challenging clinical scenario. We present the case of a patient who was refractory to standard of care but was able to achieve a durable complete remission with the combination of stereotactic body radiation therapy (SBRT), talimogene laherparepvec (TVEC), and ipilimumab.

Keywords: immunotherapy; melanoma; oncolytic viruses; radiation therapy; targeted therapeutics.

Publication types

Case Reports